Unprecedented Advances Fuel Progress in the Treatment of AL Amyloidosis
February 25th 2022Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.
Relapsed/Refractory Follicular Lymphoma Has a Bounty of Options in the Third Line
February 24th 2022Caron A. Jacobson, MD, MMSc, and a panel of experts, talk about the evolving landscape for patients with relapsed or refractory follicular lymphoma, plus data on PI3K inhibitors and CAR T-cell therapies.
Checkpoint Inhibitor Changes Take Hold: Approval Standards Stir Debate
February 16th 2022the development of PD-1/PD-L1 immune checkpoint inhibitor therapy underwent a course correction in 2021, with the withdrawal of a range of indications due to study results that failed to reach thresholds for confirming clinical benefit.